Experiences with
Chorionic villus sampling (CVS)6,680 public posts
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
[i] Abstract[/i]
[i][/i]
[i]The proliferation and survival of chronic lymphocytic leukemia (CLL) cells are heavily dependent on B-cell receptor (BCR) signaling and resistance to apoptosis. Approvals of multiple covalent Bruton's tyrosine kinas inhibitors (cBTKis) as well as the B-cell lymphoma
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL
Here's a welcome article that explains all about BTK degraders; the next class of BTK drug after the success of the FDA approved covalent BTKis (acalabrutinib/Calquence, ibrutinib/Imbruvica and zanubrutinib/Brukinsa) and non-covalent BTKi pirtobrutinib/Jaypirca.
[i][/i]
[i]"Oral therapies targeting
Want to take advantage of all our features? Just log in!
or
Additional insights from the 2023 Global Leukemia Experience Survey - CLL specific findings, unmet needs and recommendations for action
The Chronic Lymphocytic Leukemia Advocates Network (CLLAN) commissioned Picker to examine diagnostic pathways, immunity status, and treatment decision experiences of people with CLL using data from the 2023 Global Leukemia Experience Survey. The survey was commissioned by a collaboration of advocacy
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Abstract report in New England Journal of Medicine Published February 5, 2025
No real new information here and I'm surprised anyone was recruited for this study as the control arm is chemoimmunotherapy and no account appears to have been taken for unmated IGHV or 17p/TP53 as the patients were
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying CLL patients with early treatment requirement
Most of us would be aware of the prognostic value of the immunoglobulin heavy-chain variable region gene (IGHV) mutation status of our CLL (See https://healthunlocked.com/cllsupport/posts/private/146164102/the-fascinating-history-of-the-importance-of-ighv-mutation-status-in-cll-prognosis-and-treatment
Review article summarises management strategies for those with CLL harbouring complex karyotype
On 6 January 2025, the journal [i]BJ Haem[/i] published a review article titled [i]Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype[/i] written by a team from Padua, Italy. The article summary explains its aims:
[i]"Chronic lymphocytic leukaemia
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase. Phase 1 trial results.
Rocbrutinib is a new drug offering hope to patients with what are known as gatekeeper mutations that confer resistance to Pirtobrutinib. This BTKi is unique in being both a covalent and non covalent inhibitor of BTK.
Patients with gatekeeper mutations have poor outcomes and short survival and demonstrate